



Review

Pheochromocytoma and Paraganglioma: From Clinical Findings to Diagnosis

Nurcihan Aygun, Mehmet Uludag

Department of General Surgery, University of Health Sciences Turkey, Sisli Hamidiye Etfal Teaching and Research Hospital, Istanbul, Turkey

Abstract

The majority of pheochromocytoma (PCC) and paraganglioma (PGL) are endocrine active tumors, and they cause clinical symptoms by secreting excess one or more catecholamines (epinephrine, norepinephrine, and dopamine) and their inactive metabolites (metanephrine, normetanephrine, 3-metoxymetamphetamine). Although signs and symptoms regarding excess catecholamine often develop in PCC and PGL (PPGL), non-functional PPGLs may present with local compression symptoms. Persistent, sometimes worsening hypertension is the most common finding and occurs in 80-90% of the patients. Classically defined symptom triad; headache, sweating and palpitations are seen in only 25% of the patients with PCC. The difference of clinical symptoms may be related to the tumor secretion, epinephrine or norepinephrine. All patients with signs and symptoms suggestive of catecholamine excess should be screened by biochemical tests regardless of whether they have hypertension or not. Not all patients with newly diagnosed hypertension need to be screened, but only patients with additional tips for catecholamine excess should be screened. Approximately 20% of the PPGLs are diagnosed in childhood, and the male/female ratio is 2/1. 60-90% of pediatric patients present with hypertension. PPGL in pregnancy is rare, and the estimated incidence ranges between 1/15000-1/54000. Although early diagnosis is the most important factor in preventing mortality, diagnosis is not as easy as it is a rare condition. Hypertension is a common complication in pregnancy, occurring in 5-10%. Computed tomography should not be used as the imaging method during pregnancy; the first choice is magnetic resonance imaging with gadolinium or without contrast. Plasma free metanephrine or 24-hour urinary fractionated metanephrine level is recommended as a screening test for the diagnosis of PPGL in the Endocrine Society Clinical Practice Guideline. In suspicious situations, tests should be repeated. Since 40% of these patients have germline mutations, genetic tests are recommended for all patients with PPGL regardless of family history and age. Preoperative knowledge of germline mutations affects the surgical approach and the extent of adrenalectomy. After the biochemical diagnosis is made in PPGL, the tumor is localized with imaging methods to make the operation plan. In this review, we aimed to evaluate the clinical findings, diagnostic tests, and imaging studies for tumor localization in PPGL.

Keywords: Diagnosis; genetic testing; localization studies; pheochromocytoma and paraganglioma.

Please cite this article as "Aygun N, Uludag M. Pheochromocytoma and Paraganglioma: From Clinical Findings to Diagnosis. Med Bull Sisli Etfal Hosp 2020;54(3):271-280".

Pheochromocytomas (PCC) originating from the adrenal chromaffin tissue of adrenal medulla and paragangliomas (PGL) originating from extra-adrenal chromaffin tissue are rare neuroendocrine tumors. The majority of PCC and

PGL are endocrine active tumors, and they may cause clinical symptoms by secreting excess one or more catecholamines (epinephrine, norepinephrine, and dopamine) and their inactive metabolites (metanephrine, normetaneph-

Address for correspondence: Nurcihan Aygun, MD. Sisli Hamidiye Etfal Tip Uygulama ve Arastirma Merkezi, Saglik Bilimleri Universitesi, Genel Cerrahi Anabilim Dalı, Istanbul, Turkey

Phone: +90 553 277 95 78 **E-mail:** nurcihanaygun@hotmail.com

Submitted Date: June 14, 2020 **Accepted Date:** June 26, 2020 **Available Online Date:** September 08, 2020

©Copyright 2020 by The Medical Bulletin of Sisli Etfal Hospital - Available online at www.sislietfaltip.org

OPEN ACCESS This is an open access article under the CC BY-NC license (<http://creativecommons.org/licenses/by-nc/4.0/>).



rine, 3-metoxythromine). Some of them are not hormonally active.^[1,4] These tumors are abbreviated in the literature as PCC/PGL or PPGL; in this study, PPGL abbreviation will be used.^[1,4]

In this review, we aimed to evaluate the clinical findings, diagnostic tests, and imaging studies for tumor localization in PPGL.

Clinical Findings

Although signs and symptoms related to excess catecholamine often develop in PPGL, non-functional PPGLs may present with local compression symptoms.^[5]

Persistent, sometimes worsening hypertension is the most common finding and occurs in 80-90% of patients. Half of the patients with hypertension have persistent hypertension, while the other half has paroxysmal hypertension. 5-15% of patients can be normotensive.^[5] Classically defined symptom triad, headache, sweating and palpitations are seen in only 25% of patients with PCC.^[2] Other symptoms may include pallor, nausea, vomiting, constipation, flushing, weight loss, weakness, fever, orthostatic hypotension, chest and/or abdominal pain, hyperglycemia, anxiety and psychiatric findings. Myocardial infarction, arrhythmia and stroke may occur depending on the degree of catecholamine excess.^[2,6]

The difference of clinical symptoms may be related to tumor secretion, epinephrine or norepinephrine. Paroxysmal hypertension and palpitations, fainting, anxiety and hyperglycemia symptoms are more common in epinephrine-secreting PCCs. Norepinephrine-secreting PPGLs may cause more headaches, sweating and hypertension, and hypertension is more persistent, and paroxysmal condition is less.^[2] Acute (Takotsubo cardiomyopathy) or chronic (hypertrophic, dilated, obstructive) cardiomyopathy may occur with prolonged hypertension, chronic myocardial hypoxia and metabolic myocarditis due to hypercatecholaminemia. Limb ischemia, necrosis, gangrene and aortic dissection can be seen due to intense vasoconstriction. Renal function may be impaired due to vasoconstriction and even kidney failure may develop. Hypertensive retinopathy may develop in the eyes.^[5] Pheochromocytoma crisis may rarely occur. It is extremely important to differentiate this crisis from cardiogenic shock. There is multiple organ failure in this condition and the fever is above 40 °C, and additionally, there is encephalopathy, severe hypertension and/or hypotension. Treatment of this condition is the emergency resection of the tumor after the patient has been stabilized.^[5] Paroxysmal attacks can be provoked by tough exercise, sexual intercourse, defecation, alcohol intake, postural change and anesthesia. Pregnant patients

may present with secondary preeclampsia or eclampsia due to the increase in hormone secretion with the pressure of the growing uterus on the tumor. Severe paroxysmal attacks may occur during an angiography, diagnostic biopsy, surgical intervention or delivery without diagnosis or patient preparation, and these attacks may even be fatal.^[7]

Which Patients should be Screened for Pheochromocytoma/Paraganglioma?

All patients with signs and symptoms suggestive of catecholamine excess should be screened by biochemical tests regardless of whether they have hypertension or not. Not all patients with newly diagnosed hypertension need to be screened, but only patients with additional tips for catecholamine excess should be screened. Patients with blood pressure changes during conditions, such as anesthesia and surgical intervention, which are known to induce symptoms, should be screened biochemically. Apart from that, testing should be carried out in young, weak and hypertensive patients with newly diagnosed diabetes. Patients with adrenal incidentaloma should be screened for pheochromocytoma, although they have no symptoms. In addition, patients with hereditary syndromes or hereditary predisposition who may have PPGL should also be screened biochemically (Fig. 1).^[6,8]

Pheochromocytoma/Paraganglioma in Children

Approximately 20% of PPGLs are diagnosed in childhood, and the male/female ratio is 2/1. The mean age of presentation in children is 11-13. The cause of 0.5-2% of hypertension seen in children is PPGL. 60-90% of pediatric patients present with hypertension.^[9,10] 80% of PPGLs in children are hereditary, and the frequency of mutations in children is as follows: 49% VHL mutation, 15% SDHB mutation, 10% SDHD mutation, 4% NF1 mutation.^[44] In children, a second primary paraganglia develops over time, reaching 50% in 30 years after this initial diagnosis.^[44] As hereditary disease rate is high, genetic tests should be performed in all patients. All patients with genetic mutations should be followed throughout their lifetime due to the recurrence and metastatic disease.^[10]

Pheochromocytoma/Paraganglioma in Pregnancy

PPGL in pregnancy is rare and the estimated incidence ranges between 1/15000-1/54000.^[11] Mortality risk for both mother and baby is approximately 50% when PPGL is not diagnosed during pregnancy. If the prenatal diagnosis is made and appropriate treatment is performed, maternal




Figure 1. Biochemical testing algorithm in terms of clinical suspicion of PPGL.

mortality decreases to 5% and fetal mortality to 15%.^[12] In a review in which 77 births after the year 2000 were evaluated, it was reported that when the diagnosis was made prenatally, the survival was 100% for the mother and 88% for the fetus, and when the prenatal diagnosis could not be established, the mortality rate was reported to be 29% for both the mother and the fetus.^[13] In addition, maternal and fetal mortality rates in PGLs are lower than PCC; 3.6% vs. 9.8% and 12% vs. 16%, respectively. Although the mortality rate is lower in PGL, both maternal and fetal mortality are still higher than the general obstetric population.^[14] Death is due to hypertensive crisis leading to the acute coronary syndrome, cardiomyopathy, arrhythmias, stroke and shock. Although early diagnosis is the most important factor in preventing mortality, diagnosis is not easy as it is a rare condition.^[11] Hypertension is a common complication in pregnancy, occurring in 5-10%.^[15] It can be difficult to differentiate PPGL-induced hypertension due to common causes of hypertension, such as pre-existing chronic hypertension, pregnancy-related gestational hypertension and preeclampsia.^[12] Its clinical presentation in pregnancy

is not different from other patients. Approximately 90% of patients report one or more prenatal symptoms during pregnancy. However, 70% of patients can be diagnosed before birth, and 30% can be diagnosed after birth or post-mortem.^[11]

Symptoms and signs can be progressive as the pregnancy progresses. This can be explained by the stimulation of the tumor by growing uterus, uterine contractions, fetus movements and abdominal palpation.^[11, 16] In addition, estrogen is claimed to be a growth factor for adrenal tumors.^[16] These factors may sometimes induce a PPGL hypertensive crisis that includes life-threatening problems, such as acute coronary syndrome, cardiomyopathy, arrhythmias, stroke, syncope and shock. More rarely non-cardiac pulmonary edema, aortic dissection, or unexplained peripartum cardiomyopathy can be seen. It should be kept in mind that when a pregnant woman presents with one of these serious acute cardiovascular emergencies, even if she does not have known hypertension, PPGL may also exist among etiologies. The highest risk for these dangerous emergencies is associated with the peripartum period.^[11]

Catecholamines play a central role in compliance and protection against stressful stimuli during pregnancy and birth. Plasma and urine catecholamine levels do not continuously increase in healthy pregnant women.^[17] Maternal plasma catecholamine levels increase slightly even in preeclampsia.^[18] Maternal catecholamines cannot pass through the placental barriers and umbilical cord blood contains less than 10% of maternal catecholamine concentrations even in patients with PPGL. Placenta plays a key role in the protection of the fetus from tumor-induced high catecholamine levels. This is due to the presence of norepinephrine carriers and catecholamine metabolizing enzymes (such as MAO and COMT) in the placenta. These carriers facilitate norepinephrine uptake, while enzymes inactivate catecholamines.^[19] Although the fetus itself has a high secretion rate of catecholamines, an extremely effective clearance results in low catecholamine levels in the circulation.^[20] Catecholamine levels are particularly high during birth. This helps the fetus adapt to its stressful journey in the birth canal and early postnatal life.^[21]

Patients with PPGL may have sustained hypertension, paroxysmal hypertension, or paroxysmal hypertensive attacks over persistent hypertension. Sustained hypertension during pregnancy is associated with intrauterine growth retardation and accompanying adverse effects, such as preeclampsia and perinatal death. Catecholamine levels in the mother's blood may rise excessively, which may jeopardize the function of the placenta and many organs. Temporary sudden catecholamine increases in the mother's circulation can cause serious harmful effects in uteroplacental circulation. The major effect of this situation is the strong intermittent vasoconstriction in this specific and vulnerable vascular bed. This results in placental detachment and increased fetal mortality due to intrauterine hypoxia.^[11] Catecholamine levels do not change in a healthy pregnancy except for the period from the onset of labor until the second post-partum day. Urinary catecholamines increase 1.7-6.6 times in preeclamptic patients admitted to the hospital; however, plasma catecholamines tend to be decreased or normal.^[22] Biochemical tests for diagnosis are not different from other patients when there is a clinical suspicion during pregnancy. Urine or plasma free catecholamine metabolites are used for diagnosis or to exclude the diagnosis.^[11] CT should not be used as the imaging method during pregnancy; the first choice is MRI with or without gadolinium contrast.^[4, 7] Functional imaging methods are contraindicated during pregnancy.^[7, 23] Surgical intervention to the tumor during pregnancy is recommended before 24 weeks or after birth.^[11] The choice of delivery in patients with PPGL depends on various factors, such as the number of births, previous cesarean delivery, the success of

medical treatment, and personal preference of the patient. In most cases, cesarean delivery is still preferred as a way of safe delivery. Epidural, general or combined anesthetic techniques are successfully used for cesarean delivery.^[11, 23]

Diagnosis of Pheochromocytoma and Paraganglioma

Biochemical Tests

When PPGL is suspected, biochemical tests should be applied to diagnose or exclude the disease. Since plasma levels of catecholamines can be affected by many physiological and pathological conditions, and the half-life of catecholamines is very short, the suitability of serum catecholamines for diagnosis is low.^[24] In case of suspicion of PPGL, diagnosis is made by 24-hour urine measurements of catecholamines or metabolites and serum metanephrine measurements. Although fractionated urinary catecholamines are very sensitive for PCC diagnosis, their specificity is low.^[24]

24-hour urine VMA is not recommended due to its false negativity rates.^[1] Plasma free metanephrine or 24-hour urinary fractionated metanephrine level is recommended as a screening test for the diagnosis of PPGL in the Endocrine Society Clinical Practice Guideline.^[4] Although metanephrine measurement is reported to be appropriate in spot urine samples, there is no evidence to suggest this to replace 24-hour urine collection. Improper urine collection may cause false low results in children or elderly patients.

Blood samples should be taken in the supine position and after resting the patient in the supine position for at least 30 minutes to avoid false positivity.^[4] When the test is taken while standing, the false positivity rate increases 2.8 times compared to the supine position.^[25] It should not be forgotten that the serum measurement is more convenient and that the compliance is better compared to 24-hour urine collection.^[4] When urine testing is carried out, urine creatinine measurement should be done to confirm proper urine collection.^[4, 26]

The Endocrine Society recommends both serum or urine metanephrine measurements in its practice guideline, with no suggestions for the superiority of one over the other.^[4] In a recent study, it was revealed that despite the low false negativity rate of both plasma and urine free metanephrine measurements in PPGL diagnosis, it had been demonstrated that the diagnostic performance of plasma measurements is higher.^[27]

Dopamine- β -hydroxylase deficiency may also be present in PPGL, especially in SDHx mutation carriers. In this case, there is a problem in converting dopamine to norepineph-

rine, and its metabolite 3-methoxytyramine (3MT) accumulates.^[28] In this case, plasma 3-MT measurement can be used for evaluation for diagnosis.^[27]

Some rare mutation carriers have tyrosine hydroxylase deficiency, which is the limiting enzyme in catecholamine synthesis; these cases can be described as weak or non-functional.^[28] In such cases, chromogranin A in the granules in chromaffin cells can be used as a diagnostic marker as a complement to metanephrine.^[29] Many well-differentiated neuroendocrine tumors secrete chromogranin A. Many diseases and treatments can cause an increase in chromogranin A level, which would result in false positivity. Especially if the patient is using a proton-pump inhibitor (PPI), it should be stopped optimally two weeks before measurement.^[28]

Depending on the mutation, both metanephrine or normetanephrine, or only metanephrine may increase in patients with chromaffin cell tumors. In very rare cases, normetanephrine may increase alone or in combination with 3-MT.^[28]

Provocative tests have been used for the diagnosis of PCC in the past; today, biochemical tests have replaced them and these tests are not used. However, clonidine suppression test can be used to differentiate the increased secretion of norepinephrine due to sympathetic activation, which is rare and catecholamine secretion by the autonomic nervous system tumor. Clonidine suppresses catecholamine synthesis by blocking the presynaptic α_2 receptor. It is based on the suppression of catecholamine secretion in the blood taken three hours after oral 0.3 mg clonidine administration after taking the blood sample from the patient in a supine position. If it is suppressed, it favors sympathetic activity, and if not, it favors the autonomous catecholamine-secreting tumor.^[30]

Some diseases, drugs and foods cause an increase in catecholamines and metabolites, causing false positivity. Serious physical stresses, such as obstructive sleep apnea, recent surgical intervention, stroke and myocardial infarction, may cause a false increase in metanephrine. Conversely, methyl glutamine and iodine-containing contrast agents may cause false lower metanephrine levels for 72 hours after applying.^[7] The use of tricyclic antidepressants, phenoxybenzamine, α -blockers, cocaine, levodopa, MAO inhibitors, sympathomimetics (ephedrine, albuterol, amphetamine), sulfasalazine may cause increased catecholamine metabolites and cause false-positive results.^[1,2,4] Caffeine, black tea, alcohol, banana, cheese, almond, hazelnut, chocolate, egg and vanilla should be discontinued three days before the urine or serum metanephrine test.^[28] Combined increase in two or more metabolites suggests a high

probability of PPGL.^[28]

In patients undergoing PPGL screening, normal serum or urine catecholamine metabolites/catecholamine measurements may exclude the disease with high sensitivity. More than a 4-fold increase in catecholamine metabolites is most likely associated with the diagnosis of PPGL and research should be conducted by imaging methods. Tests should be repeated in cases of slight increases, such as 1-4 times the upper limit of the normal value. The above factors, which may cause false positivity, should be reassessed, and tests should be repeated after these factors are eliminated. The possibility of a tumor can be excluded if the tests are normal and if the patient does not have a high-risk clinical condition, such as a hereditary disease. Again, if an increase of 1-4 times, the upper limit of normal is detected, the clonidine suppression test can be performed in these patients. If there is a suppression of norepinephrine in the clonidine test, the tumor may most likely be excluded. If there is no suppression, the tumor should be investigated by imaging methods (Fig. 1).^[6, 8] It is recommended to perform both serum and urine tests together in the repeat test.^[2] Preoperative chromogranin A evaluation is recommended for patients with normal plasma or urinary metanephrine and normetanephrine and 3MT levels before surgery.^[31]

In summary, plasma free metanephrine and normetanephrine measurement, or 24-hour urine metanephrine and normetanephrine measurement, should be performed in PPGL screening and follow-up. In suspicious situations, tests should be repeated (Fig. 1). Particularly in cases with PGL suspicion, metastatic disease or in SDHx mutation carriers, additional 3-MT measurement is used. Chromogranin A should be measured in patients with suspected PPGL or with non-functional PPGL diagnosis.^[27]

Genetic Testing

Knowing which a patient has specific genetic basics can guide biochemical tests, specific imaging methods, and appropriate personal treatments.^[28] In the past, genetic testing was recommended for those diagnosed at a young age, or with a family history or have a multifocal disease. However, since 40% of these patients have germline mutations, genetic tests are recommended for all patients with PPGL regardless of family history and age.^[4, 31, 32] Preoperative knowledge of germline mutations affects the surgical approach and the extent of adrenalectomy.^[33] Different somatic mutations are associated with different risks of metastases, and somatic mutations, like germline mutations, may also affect prognosis. Somatic mutations may also contribute to targeted chemotherapy selection. Therefore, the analysis of somatic mutations in the extracted tumor

material can provide additional information regarding the follow-up and treatment of the patient.^[28]

Localization Studies

After the biochemical diagnosis is made in PPGL, the tumor is recommended to be localized with imaging methods to make the operation plan.^[4] Localization studies can be examined under two headlines as anatomical localization studies and functional localization studies.

Anatomical Imaging Studies

Anatomical imaging methods are computed tomography (CT) and magnetic resonance imaging (MRI). Ultrasound is not generally recommended due to its suboptimal sensitivity.^[4]

Computed Tomography

When the adrenal protocol is applied in CT for PCC, it is below 10 Hounsfield units (HU) in lipid-rich adenomas and above 10 HU in PCC in non-contrasted sections. In the adrenal protocol, a significant increase in contrast enhancement in the arterial phase and delayed venous phase washout (less than absolute 60% or relative 40% washout in the late phase in the images taken after 7-15 minutes) are detected and they can be differentiated from adrenal adenoma.^[34]

In a meta analysis of ten studies, 35% of PCC showed the washout properties of adrenal adenoma, and the mean sensitivity for adrenal washout was detected as 97%, while the specificity was 67%. In the diagnosis of PCC, other findings should be used besides the washout rate.^[35] Non-ionic contrast agents can be used safely in patients without adrenergic receptor blockade in contrast CT.^[4] Modern contrast CTs today can detect lesions over 5 mm in size.^[36] Contrast enhancement may vary depending on tumor di-

ameter, intratumoral bleeding or necrosis. CT characteristics of PGLs are similar to PCC.^[2] Although excellent results (88-100%) are reported with contrast CT in the localization of PPGL,^[4] sensitivity decreases to 65%, especially in bilateral PCC and PGLs.^[36] Since CT has excellent resolution in abdomen, pelvis and thorax, it is the first choice for anatomical imaging.^[4]

Magnetic Resonance Imaging

On MRI; PCCs, like most tumors, show hypointense signal on T1-weighted images and hyperintense signal on T2-weighted images. Despite the high sensitivity of MRI for this appearance, its specificity is low.^[37] Classically, 30% of pheochromocytomas show a "light bulb sign" in the T2-weighted images, which is a very hyperintense signal.^[36] Especially in PGLs, there is a "salt-and-pepper" appearance consisting of hypointense areas with low signal intensity corresponding to tumor vascularity and hyperintense areas seen in hemorrhagic areas of the tumor. This sign is mostly described in the head and neck region PGLs. However, this view is not specific for PGLs as it can be seen in other vascular tumors.^[37] Signal heterogeneity due to bleeding, cystic degeneration and calcifications in the tumor are helpful features in differentiating PCCs from benign adenomas. Signal characteristics of PGLs are similar to PCC in MRI, as in CT.^[37] MRI has the same sensitivity as CT in adrenal PCC and its sensitivity is close to 100% in familial PCC and PGL.^[6]

MRI is recommended in patients with metastatic PPGLs, for detection of head and neck PGLs, in patients with surgical clips that may cause artifacts in CT, in children, pregnant patients, patients with germline mutation and in patients who have been exposed to excessive radiation recently who are at risk for radiation. In patients with an intracranial

Table 1. Recommended nuclear imaging algorithm for cases of pheochromocytomas and paragangliomas by European Association of Nuclear Medicine³⁸

	First Choice	Second Choice	Third Choice (if ¹⁸ F-FDOPA or ⁶⁸ Ga-DOTA-SSA is not available)
Sporadic PCC	¹⁸ F-FDOPA or ¹²³ I-MIBG	⁶⁸ Ga-DOTA-SSA	¹⁸ F-FDG
Inherited PCC/PCL (include: NF1/RET/VHL/MAX, except:SDHx)	¹⁸ F-FDOPA	¹²³ I-MIBG or ⁶⁸ Ga-DOTA-SSA	¹⁸ F-FDG
Sporadic HNPCL	⁶⁸ Ga-DOTA-SSA	¹⁸ F-FDOPA	
Extra-adrenal sympathetic and/or multifocal and/or metastatic PGL and/or SDHx mutation	⁶⁸ Ga-DOTA-SSA	¹⁸ F-FDG and ¹⁸ F-FDOPA	¹⁸ F-FDG and ¹²³ I-MIBG

PCC: pheochromocytoma; [¹²³I]MIBG: iodine-123-labelled meta-iodobenzylguanidine; ¹⁸F-FDA: fluorine-18-labelled fluorodopamine; ¹⁸F-FDOPA: fluorine-18-labelled fluorodihydroxyphenylalanine; ¹⁸F-FDG: fluorine-18-labelled fluorodeoxyglucose; ⁶⁸Ga-DOTA-SSA: gallium-68-labelled- tetraazacyclododecanet etraacetic acid- somatostatin analogue; NF1/RET/VHL/MAX: neurofibromin 1/rearranged during transfection proto-oncogene/von Hippel-Lindau/myc-associated factor X,HNPGL: head and neck paraganglioma; SDHx: succinate dehydrogenase subunits.

aneurysm clip, MRI should not be performed as the clip may prevent the detection of small lesions at the skull base.^[4]

Functional Localization Studies

Anatomical imaging methods are generally sufficient for surgical planning in adrenal-derived PCCs. However, the decision for whether the patient needs additional whole body anatomical imaging or functional imaging is made according to the diameter of the tumor, its biochemical profile, the probability of metastasis and the possibility of the tumor being hereditary. Whole-body CT or MRI or functional radionuclide imaging is recommended to evaluate the possibility of metastatic or multiple focus, which may affect the surgical extension in all patients with PPGL, except for patients who are diagnosed as PCC less than 5 cm in size, secreting epinephrine at presentation, which has a low risk of metastasis.^[28] The sensitivity and specificity of functional imaging depend on catecholamine metabolism and secretion, glucose metabolism, tumor somatostatin receptor status and radiopharmaceutical to be used accordingly.^[2]

In functional imaging, if possible, hybrid SPECT/CT or PET/CT imaging methods are recommended, in which functional and anatomical imaging are integrated.^[38] Here, the four most frequently used nuclear imaging recently will be given. The nuclear medicine imaging recommendations of the European Association of Nuclear Medicine to be preferred in different clinical situations in PPGL are given in Table 1.

¹²³I-metaiodobenzylguanidine (¹²³I-MIBG) Scintigraphy

In this method, the scintigraphic localization of the tumor is based on the accumulation of MIBG, a norepinephrine analogue, in catecholamine producing tumors. ¹²³I-MIBG scintigraphy is recommended in cases where PCC cannot be evaluated clearly in CT or MRI. Although sensitivity in PCC is reported as 83-100% and specificity as 95-100% in small studies, in larger studies, the sensitivity decreases to 52-75% in extraadrenal, multiple, recurrent, hereditary PGLs. The sensitivity of PGLs in the head and neck region and those with SDHB mutation drops below 50%.^[38] Since ¹²³I-MIBG scintigraphy provides lower radiation and higher image quality, it is preferred over ¹³¹I-MIBG scintigraphy.^[11] For ¹²³I-MIBG scintigraphy, thyroid should be blocked by administration of 130 mg/kg (30 min to 2 h) potassium iodide to the patient one hour before the injection of the substance.^[39]

However, ¹²³I-MIBG scintigraphy is a widely used method for patient selection for ¹³¹I-MIBG treatment.^[38,39]

PET/CT with ⁶⁸Gallium-Labeled Somatostatin Analogues (⁶⁸Ga-DOTA-SSA PET/CT)

PPGLs most often express type 2 of 5 types of somatostatin receptors. Some PGLs express the type 1 receptor.^[38] Three different somatostatin analogues bound to ⁶⁸Gallium (⁶⁸Ga)-DOTA (tetraaza cyclododecane tetraacetic acid) are used to display somatostatin receptors: DOTATATE (DOTA(0)-Tyr(3)-octreotate), DOTATOC (DOTA(0)-Phe(1)-Tyr(3)-octreotide), DOTANOC (DOTA(1)-Nal(3)-octreotide).^[38] DOTATATE has a greater affinity for type 2 somatostatin receptors than others. The rate of detection of PPGL was higher than other methods with ⁶⁸Ga-DOTA-SSA PET/CT in the last meta-analysis; 93% with ⁶⁸Ga-DOTA-SST PET, 80% with ¹⁸F-FDOPA PET/CT, 74% with ¹⁸F-FDG PET/CT and 38% with ^{123/131}I-MIBG scintigraphy.^[40] Patient- and lesion-based lesion detection rate in extra-adrenal PGLs was 98% and 95% with ⁶⁸Ga-DOTA-SSA PET/CT, and was 99% and 68% with ¹⁸F-FDOPA PET/CT, respectively.^[38]

⁶⁸Ga-DOTA-SSA PET/CT can detect SDH related lesions more than ¹⁸F-FDG PET/CT.^[41] The most sensitive method for detecting, especially the head and neck PGLs, is ⁶⁸Ga-DOTA-SSA PET/CT.^[38]

¹⁸F-FDOPA PET/CT

This method is used with ¹⁸F-labeled DOPA (fluoro dihydroxyphenylalanine). Since DOPA is the precursor to all endogenous catecholamines, ¹⁸F-FDOPA is quickly taken up by PPGL tumor cells. Compared to other radiopharmaceuticals, uptake of ¹⁸F-FDOPA by normal adrenal tissue is more limited. ¹⁸F-FDOPA is very helpful in detecting small PCCs.^[42]

Sensitivity in detecting metastatic disease is 93% in SDHB negative patients and 20% in SDHB positive patients. In recent studies, it has been observed that VHL, EPAS1 (HIF2A) and FH have very high sensitivity in detecting PPGLs with multiple, recurrent and high metastatic potentials.^[38]

¹⁸F-FDG PET/CT

¹⁸F-labeled FDG (Fluorodeoxyglucose) is taken by glucose membrane transporters on the tumor cells and is generally preferred for the imaging of metastatic tumors.^[38,43]

Today, it is mostly preferred for the evaluation of patients with extra-adrenal PPGL with SDH mutation, multifocality or metastasis.^[43]

Which Imaging Method to Whom?

Abdominal contrast CT, including the entire retroperitoneal area in patients with biochemically increased metanephrine or catecholamine levels, presenting with clinical symp-

toms and findings, should be performed, or MRI in patients, where CT is not suitable. If this region is negative for the tumor, thorax, pelvis and head and neck should be scanned with MRI.^[44] CT and MRI can be combined in head and neck PGLs. 3D contrast-enhanced MR angiography increases the rate of detection of PGL in this region and contributes to the differentiation of schwannoma, plasmacytoma, meningioma and vascular malformation. In CT, jugular foramen and hypotympanum can be evaluated better in the temporal bone region.^[2]

If the incidentally detected mass in the adrenal or retroperitoneal region is >10 HU in CT, biochemical tests should be performed. If metanephrine or catecholamines are significantly increased, contrast CT or MRI should be performed.^[28] Whole-body CT or MRI or functional radionuclide imaging is recommended for preoperative metastasis evaluation in all patients with PPGL except patients with PCC below 5 cm diameter in size, secreting epinephrine, with a low probability of metastasis. Preoperative troakoabdominal CT or MRI can reveal metastases, such as peritumoral lymph node metastasis, and these can be confirmed in surgery. Functional imaging methods can reveal distant metastases that cannot be seen by anatomical imaging methods or intraoperative exploration. The rate of metastatic disease is higher in some cases. The risk of malignancy is higher in extra-adrenal PGLs than in adrenal PCCs. Patients with high 3MT levels have a high risk of malignancy. Primary metastatic tumor or recurrence is common in patients with SDHB mutation. FH and MDH2 mutations also have a high risk of metastatic disease. The European Endocrinology Society recommends functional imaging in addition to CT or MRI in high-risk patients in these categories.^[31] In addition, functional imaging methods can be used to confirm whether norepinephrine-secreting adrenal or extra-adrenal tumors are true PPGLs.

As a functional imaging method, in sporadic PCC, the first choice should be ¹⁸F-FDOPA PET/CT or ¹²³I-MIBG scintigraphy and the second choice should be ⁶⁸Ga-DOTA-SSA PET/CT. In hereditary NF1/RET/VHL/MAX mutations, the first choice should be ¹⁸F-FDOPA PET/CT scintigraphy, the second choice should be ¹²³I-MIBG or ⁶⁸Ga-DOTA-SSA PET/CT. In extra-adrenal sympathetic and/or multifocal and/or metastatic PGL and/or SDHx mutations, the first choice should be ⁶⁸Ga-DOTA-SSA PET/CT, the second choice should be ¹⁸F-FDG PET/CT and/or ¹⁸F-FDOPA PET/CT. In sporadic head and neck PGLs, the first choice should be ⁶⁸Ga-DOTA-SSA PET/CT and the second should be ¹⁸F-FDOPA PET/CT. If these methods are not applicable, in general, ¹⁸F-FDG PET/CT can be applied as the third choice for all conditions.^[38] (Table 2).

Biopsy

Biopsy is not recommended in PPGLs. Biopsy can be performed if there is an extra-adrenal tumor in the patient's history, if the tumor is nonfunctional, if the decision cannot be made with imaging whether it is benign or not and if biopsy will change the treatment of the patient. Biopsy can be considered in selected patients with potentially nonfunctional PPGL with negative biochemical tests.^[28] If a biopsy is performed in a suspicious lesion in the adrenal or retroperitoneal region, a biochemical work-up for the hormonal activity must be performed before the biopsy.^[28]

Disclosures

Peer-review: Externally peer-reviewed.

Conflict of Interest: None declared.

Authorship Contributions: Concept – N.A., M.U.; Design – N.A., M.U.; Supervision – M.U.; Materials – N.A., M.U.; Data collection &/ or processing – N.A.; Analysis and/or interpretation – M.U.; Literature search – N.A.; Writing – N.A., M.U.; Critical review – M.U.

References

1. Tevosian SG, Ghayee HK. Pheochromocytomas and Paragangliomas. *Endocrinol Metab Clin North Am* 2019;48:727–50. [\[CrossRef\]](#)
2. Patel D, Phay JE, Yen TWF, Dickson PV, Wang TS, Garcia R, et al. Update on Pheochromocytoma and Paraganglioma from the SSO Endocrine/Head and Neck Disease-Site Work Group. Part 1 of 2: Advances in Pathogenesis and Diagnosis of Pheochromocytoma and Paraganglioma. *Ann Surg Oncol* 2020;27:1329–37. [\[CrossRef\]](#)
3. Aygun N, Uludag M. Pheochromocytoma and Paraganglioma: From Epidemiology to Clinical Findings. *Sisli Etfal Hastan Tip Bul* 2020;54:159–68. [\[CrossRef\]](#)
4. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2014;99:1915–42. [\[CrossRef\]](#)
5. Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. *Endocrinol Metab Clin North Am* 2011;40:295–311. [\[CrossRef\]](#)
6. Kiernan CM, Solórzano CC. Pheochromocytoma and Paraganglioma: Diagnosis, Genetics, and Treatment. *Surg Oncol Clin N Am* 2016;25:119–38. [\[CrossRef\]](#)
7. Frunzac RW, Grant CS. Pheochromocytoma. In: Clark OH, Duh QY, Kebebew E, Gosnell JE, Shen WT, editors. *Textbook of Endocrine Surgery*. 3rd ed. Jaypee Brothers Medical Publishers; 2016. p. 1047–67. [\[CrossRef\]](#)
8. van Berkel A, Lenders JW, Timmers HJ. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma. *Eur J Endocrinol* 2014;170:R109–19. [\[CrossRef\]](#)
9. Bholah R, Bunchman TE. Review of Pediatric Pheochromocytoma and Paraganglioma. *Front Pediatr* 2017;5:155. [\[CrossRef\]](#)

10. Bausch B, Wellner U, Bausch D, Schiavi F, Barontini M, Sanso G, et al. Long-term prognosis of patients with pediatric pheochromocytoma. *Endocr Relat Cancer* 2013;21:17–25. [\[CrossRef\]](#)
11. Lenders JWM, Langton K, Langenhuijsen JF, Eisenhofer G. Pheochromocytoma and Pregnancy. *Endocrinol Metab Clin North Am* 2019;48:605–17. [\[CrossRef\]](#)
12. Lenders JW. Pheochromocytoma and pregnancy: a deceptive connection. *Eur J Endocrinol* 2012;166:143–50. [\[CrossRef\]](#)
13. Biggar MA, Lennard TW. Systematic review of phaeochromocytoma in pregnancy. *Br J Surg* 2013;100:182–90. [\[CrossRef\]](#)
14. Wing LA, Conaglen JV, Meyer-Rochow GY, Elston MS. Paraganglioma in Pregnancy: A Case Series and Review of the Literature. *J Clin Endocrinol Metab* 2015;100:3202–9. [\[CrossRef\]](#)
15. Vest AR, Cho LS. Hypertension in pregnancy. *Curr Atheroscler Rep* 2014;16:395. [\[CrossRef\]](#)
16. van der Weerd K, van Noord C, Loeve M, Knapen MFCM, Visser W, de Herder WW, et al. Endocrinology in pregnancy: Pheochromocytoma in pregnancy: case series and review of literature. *Eur J Endocrinol* 2017;177:R49–58. [\[CrossRef\]](#)
17. Natrajan PG, McGarrigle HH, Lawrence DM, Lachelin GC. Plasma noradrenaline and adrenaline levels in normal pregnancy and in pregnancy-induced hypertension. *Br J Obstet Gynaecol* 1982;89:1041–5. [\[CrossRef\]](#)
18. Oian P, Kjeldsen SE, Eide I, Maltau JM. Increased arterial catecholamines in pre-eclampsia. *Acta Obstet Gynecol Scand* 1986;65:613–7. [\[CrossRef\]](#)
19. Nguyen TT, Tseng YT, McGonnigal B, Stabila JP, Worrell LA, Saha S, et al. Placental biogenic amine transporters: in vivo function, regulation and pathobiological significance. *Placenta* 1999;20:3–11.
20. Bzoscik L, Blount L, Kashiwai K, Tseng YT, Hay WW Jr, Padbury JF. Placental norepinephrine clearance: in vivo measurement and physiological role. *Am J Physiol* 1995;269:E145–9. [\[CrossRef\]](#)
21. Slotkin TA, Seidler FJ. Adrenomedullary catecholamine release in the fetus and newborn: secretory mechanisms and their role in stress and survival. *J Dev Physiol* 1988;10:1–16.
22. Affinati AH, Auchus RJ. Endocrine causes of hypertension in pregnancy. *Gland Surg* 2020;9:69–79. [\[CrossRef\]](#)
23. Kamoun M, Mnif MF, Charfi N, Kacem FH, Naceur BB, Mnif F, et al. Adrenal diseases during pregnancy: pathophysiology, diagnosis and management strategies. *Am J Med Sci* 2014;347:64–73.
24. Lal G, Clark OH. Thyroid, parathyroid and adrenal. In: Brunicaardi FC, Andersen DK, Billiar TR, Dunn DL, Kao LS, Hunter JG, et al, editors. *Schwartz's Principles of Surgery*. 11th ed. Newyork: McGraw Hill; 2019. p. 1625–704.
25. Lenders JW, Willemsen JJ, Eisenhofer G, Ross HA, Pacak K, Timmers HJ, et al. Is supine rest necessary before blood sampling for plasma metanephrines? *Clin Chem* 2007;53:352–4. [\[CrossRef\]](#)
26. Cisco RM, Grondal S, Hamberger B. Adrenal physiology. In: Clark OH, Duh QY, Kebebew E, Gosnell JE, Shen WT, editors. *Textbook of Endocrine Surgery*. 3rd ed. Jaypee Brothers Medical Publishers; 2016. p. 973–78. [\[CrossRef\]](#)
27. Eisenhofer G, Prejbisz A, Peitzsch M, Pamporaki C, Masjkur J, Rogowski-Lehmann N, et al. Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. *Clin Chem* 2018;64:1646–56. [\[CrossRef\]](#)
28. Nölting S, Ullrich M, Pietzsch J, Ziegler CG, Eisenhofer G, Grossman A, et al. Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. *Cancers (Basel)* 2019;11:1505. [\[CrossRef\]](#)
29. Bílek R, Vlček P, Šafařík L, Michalský D, Novák K, Dušková J, et al. Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma. *Cancers (Basel)* 2019;11:586. [\[CrossRef\]](#)
30. McHenry CM, Hunter SJ, McCormick MT, Russell CF, Smye MG, Atkinson AB. Evaluation of the clonidine suppression test in the diagnosis of phaeochromocytoma. *J Hum Hypertens* 2011;25:451–6. [\[CrossRef\]](#)
31. Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, et al; Guideline Working Group. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. *Eur J Endocrinol* 2016;174:G1–10. [\[CrossRef\]](#)
32. Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL; Guideline Development Group, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee and National Society of Genetic Counselors Practice Guidelines Committee. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. *Genet Med* 2015;17:70–87. [\[CrossRef\]](#)
33. Nockel P, El Lakis M, Gaitanidis A, Yang L, Merkel R, Patel D, et al. Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery. *Surgery* 2018;163:191–6. [\[CrossRef\]](#)
34. Čtvrtlík F, Koranda P, Schovánek J, Škarda J, Hartmann I, Tüdös Z. Current diagnostic imaging of pheochromocytomas and implications for therapeutic strategy. *Exp Ther Med* 2018;15:3151–60.
35. Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Pheochromocytoma as a frequent false-positive in adrenal washout CT: A systematic review and meta-analysis. *Eur Radiol* 2018;28:1027–36. [\[CrossRef\]](#)
36. Wiseman D, Lakis ME, Nilubol N. Precision Surgery for Pheochromocytomas and Paragangliomas. *Horm Metab Res* 2019;51:470–82. [\[CrossRef\]](#)
37. Itani M, Mhlanga J. Imaging of Pheochromocytoma and Paraganglioma. In: Mariani-Costantini R, editor. *Paraganglioma: A Multidisciplinary Approach*. Brisbane (AU): Codon Publications; 2019 Jul 2. Chapter 3. [\[CrossRef\]](#)
38. Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. *Eur J Nucl Med Mol Imaging* 2019;46:2112–37. [\[CrossRef\]](#)

39. Friedman NC, Hassan A, Grady E, Matsuoka DT, Jacobson AF. Efficacy of thyroid blockade on thyroid radioiodine uptake in 123I-mIBG imaging. *J Nucl Med* 2014;55:211–5. [\[CrossRef\]](#)
40. Han S, Suh CH, Woo S, Kim YJ, Lee JJ. Performance of 68Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis. *J Nucl Med* 2019;60:369–76. [\[CrossRef\]](#)
41. Kan Y, Zhang S, Wang W, Liu J, Yang J, Wang Z. 68Ga-somatostatin receptor analogs and 18F-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis. *Acta Radiol* 2018;59:1466–74.
42. Taïeb D, Jha A, Guerin C, Pang Y, Adams KT, Chen CC, et al. 18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma. *J Clin Endocrinol Metab* 2018;103:1574–82. [\[CrossRef\]](#)
43. Antonio K, Valdez MMN, Mercado-Asis L, Taïeb D, Pacak K. Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. *Gland Surg* 2020;9:105–23. [\[CrossRef\]](#)
44. Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and Paraganglioma. *N Engl J Med* 2019;381:552–65. [\[CrossRef\]](#)